These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 11685175)

  • 21. Cardiometabolic Risk Factors and Incident Cardiovascular Disease Events in Women vs Men With Type 1 Diabetes.
    Braffett BH; Bebu I; El Ghormli L; Cowie CC; Sivitz WI; Pop-Busui R; Larkin ME; Gubitosi-Klug RA; Nathan DM; Lachin JM; Dagogo-Jack S;
    JAMA Netw Open; 2022 Sep; 5(9):e2230710. PubMed ID: 36074461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nurses' observational study on the practice of secondary prevention in a cardiovascular department.
    Steffenino G; Galliasso M; Gastaldi C; Ricca N; Mangiacotti B
    Ital Heart J; 2003 Jul; 4(7):473-8. PubMed ID: 14558299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.
    White HD; Stewart RAH; Dalby AJ; Stebbins A; Cannon CP; Budaj A; Linhart A; Pais P; Diaz R; Steg PG; Krug-Gourley S; Granger CB; Hochman JS; Koenig W; Harrington RA; Held C; Wallentin L;
    Am Heart J; 2020 Jul; 225():97-107. PubMed ID: 32480059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.
    Velussi M; Cernigoi AM; Tortul C; Merni M
    Diabetes Nutr Metab; 1999 Dec; 12(6):407-12. PubMed ID: 10782562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
    Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids).
    Elshazly MB; Martin SS; Blaha MJ; Joshi PH; Toth PP; McEvoy JW; Al-Hijji MA; Kulkarni KR; Kwiterovich PO; Blumenthal RS; Jones SR
    J Am Coll Cardiol; 2013 Nov; 62(21):1960-1965. PubMed ID: 23973689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
    J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis.
    Ahmed HM; Miller M; Nasir K; McEvoy JW; Herrington D; Blumenthal RS; Blaha MJ
    Am J Epidemiol; 2016 May; 183(10):875-83. PubMed ID: 27189327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice.
    Faggiano P; Fattirolli F; Frisinghelli A; Piccioli L; Dasseni N; Silverii MV; Albricci L; D'Ambrosio G; Garrì R; Esposito L; Giallauria F
    Monaldi Arch Chest Dis; 2019 May; 89(2):. PubMed ID: 31107039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men.
    McFarlane SI; Castro J; Kaur J; Shin JJ; Kelling D; Farag A; Simon N; El-Atat F; Sacerdote A; Basta E; Flack J; Bakris G; Sowers JR
    J Clin Hypertens (Greenwich); 2005 Feb; 7(2):73-80. PubMed ID: 15722651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Turkish assessment of SURF (SUrvey of Risk Factor Management) study: Control rates of cardiovascular risk factors derived from databases of 15 different levels of health centers in Turkey.
    Tokgözoğlu L; Oğuz A; Balcı MK; Temizhan A; Güldal Altunoğlu E; Bektaş O; Aslan G; Iyigün Ö; Kara A; Tanrıverdi Pınar H; Yavuz S; Tekin M; Ercan S; Çelik S; Sezgin Meriçliler Ö; Bozkurt Çakır İ
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):398-407. PubMed ID: 28694393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP; Pépin GM; Mahley RW
    Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a 36-month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients.
    Neto PR; Marusic S; de Lyra Júnior DP; Pilger D; Cruciol-Souza JM; Gaeti WP; Cuman RK
    J Pharm Pharm Sci; 2011; 14(2):249-63. PubMed ID: 21733413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lipid control in patients with coronary artery disease in a healthcare area in Cáceres (Spain): LIPICERES study].
    Gómez-Barrado JJ; Ortiz C; Gómez-Turégano M; Gómez-Turégano P; Garcipérez-de-Vargas FJ; Sánchez-Calderón P
    Clin Investig Arterioscler; 2017; 29(1):13-19. PubMed ID: 28062171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
    Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH
    Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.